TP53 and Parkinson disease: Indeed, pharmacological inhibition of p53, via pifithrin-α (PFT-α) and Z-1-117 or genetic reduction of p53, has been shown to reverse neurodegeneration in multiple PD models, raising the potential of p53 as a therapeutic target for PD [148,149,215].